Effects of testosterone replacement in hypogonadal men

Area of Science:

• Endocrinology
• Men's Health
• Metabolic Medicine

Background:

• Hypogonadism is linked to adverse effects on bone, muscle, and overall well-being.
• Previous testosterone studies often used pharmacological doses or had short durations.
• Untreated hypogonadal men require assessment of physiological testosterone replacement effects.

Purpose of the Study:

• To evaluate the magnitude and time course of physiological testosterone replacement therapy (TRT) effects.
• To assess TRT impact on bone density, muscle mass/strength, erythropoiesis, prostate volume, energy, sexual function, and lipids.
• To study these effects over 3 years in previously untreated hypogonadal men.

Main Methods:

• 18 untreated hypogonadal men were enrolled.
• Transdermal testosterone was administered for 3 years.
• Outcomes including bone density, body composition, strength, hematocrit, prostate volume, energy, sexual function, and lipids were monitored.

Main Results:

• Significant increases in lumbar spine (7.7%) and femoral trochanter (4.0%) bone mineral density were observed, peaking at 24 months.
• Fat-free mass increased by 3.1 kg within 6 months.
• Hematocrit, prostate volume, energy levels, and sexual function showed significant improvements within 3-6 months.
• No significant changes in fat mass or muscle strength were noted.
• Lipid profiles remained unchanged.

Conclusions:

• Physiological testosterone replacement therapy effectively improves bone density, increases fat-free mass, and enhances erythropoiesis, prostate volume, energy, and sexual function in hypogonadal men.
• Bone density benefits accrue over 24 months, while other effects manifest within 3-6 months.
• These findings provide a basis for monitoring TRT efficacy and timing in hypogonadal men.